Now that 2023 is firmly in the rearview, we can say without a doubt that it was a remarkable year for stocks. The benchmark S&P 500 index soared 24% last year, and the Dow Jones Industrial Average reached a new record high.Last year wasn't a rotten one for these two stocks, but they didn't keep pace with the benchmark index. These laggards that underperformed last year have been under enough pressure that they offer above-average dividend yields at the moment. Above-average yields aren't much good to income ...

S&P 500股息贵族公司情况 - S&P 500股息贵族每年一月进行重新平衡，目前有66家公司入选[3] - 大多数S&P 500股息贵族公司股价过高，导致股息率较低，但有三家公司的年度股息超过了单股价格[4] - 在股息率排名前十的公司中，有三家公司是Amcor PLC (AMCR), Franklin Resources Inc (BEN)和Walgreens Boots Alliance (WBA)，另外一家公司是Hormel Foods (HRL)[5] - 分析师预测到2025年1月，十家股息贵族公司的净收益率在9.71%到26.77%之间[7] - 预测2024-2025年度十大S&P500股息贵族公司的净收益率，其中包括Exxon Mobil Corp (XOM)、Chevron Corp (CVX)、Air Products & Chemicals (APD)等公司[8] - Exxon Mobil Corp (XOM)的预期净收益为267.69美元，基于24位分析师的中位数目标价格估计[9] - Chevron Corp (CVX)的预期净收益为225.05美元，基于14位分析师的中位数目标价格估计[10] - Air Products and Chemicals (APD)的预期净收益为150.80美元，基于23位分析师的中位数目标价格估计[11] - 除了上述公司外，还有Genuine Parts Co (GPC)、PepsiCo Inc (PEP)、NextEra Energy Inc (NEE)等公司也被预测为高收益公司[12][13][14] 股息贵族公司收益情况 - 股息狗规则指出，高收益股票通常被称为“狗股”，这些股票通常具有可靠的股息和较高的收益率[21] - 根据经纪人的目标，前50家股息贵族公司中，3M Co、Realty Income Corp和Federal Realty Investment Trust等公司排名前三[27][28][29] - 2024年1月S&P500股息贵族中，有10家公司的股价上涨了7.65%至24.00%[32] - 分析师预计2025年1月，10家最高股息收益率的股息贵族中，5家最低价股的预期收益率将比全部10家的预期收益率低17.71%[34] - 2023年S&P股息贵族中，有5家最低价股的预期收益率为4.05%，而全部10家的预期收益率为4.92%[38] - 10家最高股息收益率的股息贵族中，有3家公司的年度股息收入超过了$1,000美元的投资金额[44]

业绩总结 - 公司重点关注于在2025年实现强劲增长，特别是在五大关键治疗品牌Skryizi, Rinvoq, Ubrelvy, Vraylar, QULIPTA以及美容产品组合方面[5] - 公司在电话会议中提到，2024年预计Humira的销售额将超过分析师预期的$7亿[33] - 由于公司增加了回扣以维持对Humira的平价访问，预计2024年的销售额主要受价格影响[37] - 公司计划在2026年前将杠杆率降至两倍[30] - 公司将继续寻找能够推动未来增长的资产，但将主要关注规模较小、早期阶段的交易[31] - 公司预计2025年开始实现营运利润率的扩张，因为公司有能力在46%至47%的范围内运营[29] - 公司对于未来十年的增长平台表现充满信心，预计到2028年，两笔交易将相互抵消[27] - 公司对于2024年Humira的销售预期较为乐观，预计将超过之前的预期[34] - 公司将继续寻找能够推动未来增长的资产，但将主要关注规模较小、早期阶段的交易[32] - 公司对于2025年及以后的营运利润率扩张充满信心，预计将实现营运利润率的扩张[29] - 公司对于2024年Humira的销售预期较为乐观，预计将超过之前的预期[34] 产品展望 - 公司重点关注于在2025年实现强劲增长，特别是在五大关键治疗品牌Skryizi, Rinvoq, Ubrelvy, Vraylar, QULIPTA以及美容产品组合方面[5] - Skyrizi和Rinvoq在各大适应症中持续取得强劲的市场份额增长，特别是在炎症性肠病领域[6][7] - 神经科学领域的增长也非常可观，特别是Vraylar在抑郁症治疗中的增长以及口服类肽相关药物Ubrelvy和QULIPTA的国际市场扩张[10][11] - 美容产品市场正在逐渐复苏，Botox和填充剂市场表现良好，公司保持了领先市场份额的地位[12][13] - 公司在眼科领域也有着稳定的业务，未来将关注基因治疗领域的发展，特别是在湿性年龄相关性黄斑变性和糖尿病视网膜病变方面[16] - 公司将关注重要的产品管线里程碑，包括Skryizi和951的全球上市，以及Teliso-V、lutikizumab和383等产品的进展[17] 市场展望 - 公司在电话会议中提到，2024年预计Humira的销售额将超过分析师预期的$7亿[33] - 由于公司增加了回扣以维持对Humira的平价访问，预计2024年的销售额主要受价格影响[37] - 公司计划在2026年前将杠杆率降至两倍[30] - 公司将继续寻找能够推动未来增长的资产，但将主要关注规模较小、早期阶段的交易[31] - 公司预计2025年开始实现营运利润率的扩张，因为公司有能力在46%至47%的范围内运营[29] - 公司对于未来十年的增长平台表现充满信心，预计到2028年，两笔交易将相互抵消[27]

AbbVie Inc. (NYSE:ABBV) J.P. Morgan 42nd Annual Healthcare Conference January 10, 2024 11:15 AM ET Company Participants Rob Michael - President and Chief Operating Officer Jeff Stewart - Chief Commercial Officer Roopal Thakkar - Chief Medical Officer Conference Call Participants Chris Schott - J.P.Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P.Morgan, and it's my pleasure to be hosting a fireside chat today with AbbVie. From the company, we have Rob Michael, President and Chief Operati ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +6.7%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 8%. The key question now is: What could be the stock's future direction?While media releases or ...

股价表现 - AbbVie (ABBV)最新收盘价为$162.31，较前一交易日上涨了0.55%[1] - AbbVie股价在过去一个月中上涨了6.74%，超过了医药行业的6.58%和标普500指数的3.5%[2] 财务预期 - AbbVie即将公布2024年2月2日的财报，预计每股收益为$2.93，同比下降18.61%，营收预期为$14.04亿，同比下降7.14%[3] 分析评级 - AbbVie目前的Zacks Rank为3 (Hold)，Zacks Consensus EPS预期在过去30天内增长了0.31%[6]

Whether it's knowing about an underutilized data source or using an alternative investment strategy, every investor needs a few special tools in their toolkit because it's part of developing an edge in the market.However, don't assume that you need complicated processes or obscure knowledge to become better at investing than you are right now. In fact, there are three straightforward tricks that'll deliver quite a bit of value right away, so let's review each one.1. Invest in pairs or groups of competitorsH ...

-    PRODUODOPA® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease -   PRODUODOPA demonstrated sustained improvements in "Off" time (when symptoms return between medication doses), "On" time (when symptoms are controlled) without dyskinesia (involuntary movement), and morning akinesia ("Off" time upon waking) NORTH CHICAGO, Ill., Jan. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the launch ...

AbbVie Inc. (ABBV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ABBV's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typical ...

AbbVie汗腺炎治疗 - AbbVie宣布Phase 2结果显示，接受lutikizumab治疗的中度至重度汗腺炎患者在16周时取得更高的HiSCR 50响应率[2] - Lutikizumab是AbbVie的一种正在研究中的双变量结构域白细胞介素（IL）1α/1β拮抗剂，研究表明IL 1α和1β在汗腺炎病变中升高[2] - AbbVie将继续推进lutikizumab在汗腺炎症状中的临床项目至Phase 3，以进一步了解其在中度至重度汗腺炎患者中的应用[3]